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ABSTRACT
Introduction: Systemic sclerosis (SSc) is a complex autoimmune connective tissue disease characterized
by chronic and progressive tissue and organ fibrosis with broad patient-to-patient variability.
Some risk factors are known and include combination of persistent Raynaud’s phenomenon, steroid
hormone imbalance, selected chemicals, thermal, or other injuries. Endogenous and/or exogenous
environmental trigger/risk factors promote epigenetic mechanisms in genetically primed subjects.
Disease pathogenesis presents early microvascular changes with endothelial cell dysfunction, followed
by the activation of mechanisms promoting their transition into myofibroblasts. A complex autoimmune
response, involving innate and adaptive immunity with specific/functional autoantibody production,
characterizes the disease. Progressive fibrosis and ischemia involve skin and visceral organs resulting in
their irreversible damage/failure. Progenitor circulating cells (monocytes, fibrocytes), together with growth
factors and cytokines participate in disease diffusion and evolution. Epigenetic, vascular and immunologic
mechanisms implicated in systemic fibrosis, represent major targets for incoming disease modifying
therapeutic approaches.
Areas covered: This review discusses current understanding and new insights of SSc pathogenesis,
through an overview of the most relevant advancements to present aspects and mechanisms involved in
disease pathogenesis.
Expert opinion: Considering SSc intricacy/heterogeneity, early combination therapy with vasodilators,
immunosuppressive and antifibrotic drugs should successfully downregulate the disease progression,
especially if started from the beginning.
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1. Introduction
Systemic sclerosis (SSc) is a complex autoimmune connective
tissue disease characterized by chronic and progressive tis-
sue and organ fibrosis. Triggers for SSc remain only partially
defined, whereas different risk factors have been identified
and include combination of long-lasting Raynaud’s phenom-
enon (RP), selected chemicals and silicone breast implants,
frequent thermal or other mechanical injuries, mainly at acral
regions of the body, and steroid hormone imbalance/stress
[1,2]. Both endogenous and/or exogenous environmental
trigger/risk factors are important promoters for epigenetic
mechanisms in genetically primed subjects.
The pathophysiology of SSc is a progressive self-amplifying
process, which first implicates the microvascular damage, fol-
lowed by the autoimmune response and inflammation, and
diffuse fibrosis (Figure 1) [3,4]. In conclusion, the different patho-
physiological steps are finally associated with a progressive fibro-
tic involvement of skin and internal organs (Figure 1).
Current understanding of SSc has permitted the production
of new biological drugs against disease-specific molecular tar-
gets to actuate disease-modifying therapeutic approaches. In
this review, we summarize and discuss the current understand-
ing and new insights into the pathogenesis of SSc.
2. The microvascular pathophysiology: current
understanding
It is known that RP is a common episodic color change of the
extremities in response to cold exposure, which is highly
prevalent in patients with SSc (over 95% of patients have RP)
[5]. Patients with primary RP progress in almost 15% of cases
to secondary RP associated with SSc [6]. In fact, the initial but
reversible microvascular damage induced by primary RP in the
presence of other risks factors and enhanced immune
response, progress to secondary RP, with irreversible micro-
vessel deletion, capillary destruction, and subsequent increase
in tissue fibrosis.
Secondary RP (SRP) is very often the first manifestation of
SSc and may precede other organ disease signals by years.
Almost every SSc patient experiences frequent ischemic events
typical of RP and is associated with severe events, which are
pronounced in the extremities i.e. in the fingers with recurrent
digital ulcers in 25–50% of cases [5].
Evidence suggests that SRP in SSc results from
a microvasculopathy involving all layers of the peripheral
blood vessels and in part it is caused by the dysfunction of
the endothelium [7]. The endothelium is a metabolically
active tissue that, under normal circumstances, regulates
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regional blood flow, transportation of nutrients, coagulation
and fibrinolysis, and migration of blood cells while main-
taining an antithrombotic lining in the vasculature.
These important biologic functions are achieved through
production of a complex array of molecules including
vasodilators (i.e. nitric oxide (NO) and prostacyclin), vaso-
constrictors (i.e. endothelin-1 (ET-1) and platelet activating
factor), and cell adhesion molecules (i.e. selectins and
integrins) [8].
An abnormal function of the endothelium results in an
imbalance of vasoactive factors including overproduction of
the vasoconstrictor ET-1 in skin, lung tissue and serum and
underproduction of the vasodilator NO and prostacyclin in
SSc patients.
In particular, ET-1 plays a prominent role in vascular tone
regulation through its receptors ET
A
and ET
B
. ET
A
receptor
predominates on vascular smooth muscle and mediates vaso-
constriction, whereas the ET
B
receptor subtype, when presents
on vascular endothelium, mediates vasodilation through NO
release [9–11].
The frequent and sustained alteration of the microvascular
tone is a noxious trigger to the endothelial barrier leading to
opening of the endothelial junctions, further inflammatory
cells homing, increased microvessel permeability and contin-
uous vascular leak (Figure 2).
The phenomenon of progressive microvascular leak causes
microhemorrhages and local edema (Figure 2) [12].
Platelet activation is demonstrated in SSc leading to the
release of thromboxane, a potent vasoconstrictor. In addi-
tion, activated endothelial cells show an increased expres-
sion of the adhesion molecules vascular cell adhesion
protein 1 (VCAM1), intercellular adhesion molecule (ICAM)
and E-selectin, resulting in recruitment of inflammatory cells
from the circulation (Figure 2) [12].
The cutaneous disease of SSc is also associated with
a decreased release from sensory nerves of vasodilatory
neuropeptides, such as calcitonin gene-related peptide
(CGRP) and serotonin [13,14], further triggering vasospasm
already with little provocation. Finally, there is evidence of
upregulation of the vascular smooth muscle α2c adrenocep-
tor (α2c-AR) that can enhance vasoconstrictive responses to
stress or cold stimuli [5].
Severe vasospasm of digital arteries and cutaneous thermo-
regulatory vessels is observed in SSc with repeated bouts of
vasoconstriction that potentially may cause severe obstacle to
the microcirculation and ischemia-reperfusion injury of tis-
sues [15].
Together with the prolonged ischemia-reperfusion induced
by the RP, other toxic stimuli may induce a state of persistent
endothelial activation resulting in apoptosis, cell detachment,
and microvascular damage (Figure 2).
Article highlights
● Systemic sclerosis (SSc) is a complex autoimmune connective tissue dis-
ease characterized by a chronic and progressive tissue and organ fibrosis.
● The pathophysiology of SSc is a progressive self-amplifying process,
that first implicates the microvascular/endothelial damage, followed
by the autoimmune response and inflammation, and finally charac-
terized by diffuse fibrosis.
● The progressive microvascular pathophysiology in SSc is associated
with the clinical disease progression: from the Raynaud’s phenom-
enon to the microvessel leak with hemorrhages, capillary collapses/
loss (both visible on capillaroscopy) and tissue ischemia.
● New insights on the microvascular SSc pathophysiology include VEGF
isoforms (antiangiogenic) and impaired functioning of the endothelial
progenitor cells (EPC) that are involved in the angiogenesis.
● Epigenetic studies have identified intrinsic alterations in SSc fibro-
blasts resulting from epigenetic changes, as well as altered microRNA
expression (in particular miR-29, miR-155) that might underlie the
persistent activation phenotype of these cells.
● The immune response in SSc is complex and involves both the innate
and adaptive immunity with prevalence of Th2 cytokines.
● The macrophage (M) polarization versus a prevalence of hybrid M1/M2
circulating progenitor cells and versus the M2 phenotype in the fibrotic
tissues, it is particularly evident in presence of SSc lung involvement.
● The production of specific autoantibodies in SSc seems associated
with different clinical aspects, in addition several functional autoanti-
bodies seem implicated in the pathophysiology of the disease.
● The fibrotic process in SSc is characterized by progressive tissue accu-
mulation of extracellular matrix (ECM) protein like collagens, elastin,
glycosaminoglycans, tenascin and fibronectin isoforms in skin andmulti-
ple organs.
● The endothelial(epitelial)-to-mesenchymal cell transition (EndoMT) pro-
cess is a source of myofibroblasts in SSc and can be induced by TGF-β
together with endothelin-1 (ET-1): both seem to be pivotal soluble
players in the development of fibrosis.
● In SSc, myofibroblasts seem to originate also from adiponectin-positive
intradermal progenitor cells: the process was confirmed by adipocyte
phenotype investigations and is termed adipocyte-myofibroblast tran-
sition (AMT).
Figure 1. The figure reports the progression of the pathophysiological process and the corresponding clinical body involvement in systemic sclerosis (the rate of
progression is different from patient to patient).
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3. The microvascular pathophysiology: new insights
In SSc, the microvascular damage is paralleled by an increased
production of pro-angiogenic factors (e.g. VEGF-A, ET-1) and on
the other hand defective response of the damaged endothelial
cells (Figure 2) [16].
However, despite the increase of VEGF-A in SSc skin and
serum, a clear evidence of an insufficient angiogenic response
persists [17].
New insights showed the existence of a pro-angiogenic
VEGF165 isoform and an antiangiogenic VEGF165b isoform gen-
erated by alternative splicing in VEGF-A pre-mRNA [18,19].
The anti-angiogenic VEGF165b isoform V appears overex-
pressed in SSc dermis in different cell types, including endothelial
cells, perivascularmononuclear inflammatory cells, and fibroblasts.
In addition, the increased VEGF165b serum levels correlate
with degree of nailfold capillary altered array and loss and SSc
dermal microvascular endothelial cells (MVECs) express and
release elevated levels of VEGF165b.
A recent study showed that, in SSc, platelets store high con-
centrations of VEGF165b and therefore they may be a major
source of circulating VEGF165b especially following their activa-
tion on contact with the damaged SSc endothelium [20].
Interestingly, binding of VEGF165 to vascular endothelial
growth factor receptor (VEGFR)-2 triggers endothelial cell prolif-
eration, survival, and migration, which are fundamental for the
process of angiogenesis [21]. On the contrary, when VEGF165b
binds to VEGFR-2 with the same affinity as VEGF165, phosphor-
ylation/activation of VEGFR-2 generates an incomplete down-
stream signaling.
A very recent investigation has shown that increased
VEGF
165
b expression and secretion by macrophages induce
an anti-angiogenic M1-like phenotype that directly impairs
angiogenesis [22]. This finding, up to now, is limited to the
atherosclerotic occlusions and decrease blood flow to the
lower limbs, causing ischemia and tissue loss in patients with
peripheral artery disease (PAD) [22].
In particular, VEGFR1 inhibition by VEGF
165
b results in
S100A8/S100A9-mediated calcium influx to induce an M1-like
phenotype that impairs ischemic muscle revascularization and
perfusion recovery (Figure 2).
In SSc, a new emerging link between microvascular
damage, endothelial dysfunction, and development of dermal
fibrosis is represented by the endothelial-to-mesenchymal
transition (EndoMT) process. EndoMT is a trans-differentiation
process by which endothelial cells lose the ability to express
their phenotype markers as well as their morphology and
express mesenchymal cell products, such as α-smooth muscle
actin (α-SMA) and collagen type I (COL-1), acquiring mesench-
ymal/myofibroblast features [23,24]. The EndoMT process
seems to be mediated by vasoconstrictor molecules and
growth factors, including ET-1 and transforming growth factor
(TGF), probably as a consequence of the imbalance of vasoac-
tive factors due to the abnormal function of the endothelium
[25]. The EndoMT process might be responsible for the pre-
sence of an abnormal microvascular architecture, which may
determine the capillary loss in SSc patients characterized by an
active disease.
Further insights concern the angiogenic potential of
endothelial cell (EC)-like mesenchymal stromal cells that was
found to be reduced after being stimulated with VEGF and
stromal cell-derived factor-1 in vitro, suggesting that endothe-
lial repair may be affected in SSc starting from the bone
marrow (BM) [26]. In this context, the pathologic endothelium,
Figure 2. The figure describes the early steps on the systemic sclerosis pathophysiology involving the microvascular endothelium. The frequent and sustained alteration
of the microvascular tone and cell apoptosis, are noxious trigger to the endothelial barrier leading to opening of the endothelial junctions, further inflammatory cells
migration and homing, increased microvessel permeability and progressive vascular leak.
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via the altered cross-talk between ECs, mesenchymal stem
cells (MSCs) and pericytes impairs the angiogenic process
and modulate the production of profibrotic molecules in
MSCs, promoting a switch of these multipotent perivascular
cells toward a profibrotic myofibroblast phenotype [25]. MSCs
from SSc patients showed intrinsic differentiation abnormal-
ities in response to several profibrotic molecules, such as TGF-
β1, and a disease-associated microenvironment, favoring
a phenotypic switch toward myofibroblasts [27]. As a matter
of fact, the role of the EndoMT, the cross-talk between ECs and
pericytes, as well as the commitment of mesenchymal stem
cells toward a profibrotic phenotype represent an important
contribution the pathophysiology of SSc [28,29].
Endothelial progenitor cells (EPC) normally have the ability
to develop into fully mature endothelial cells and contribute to
neovascularization by targeting sites of endothelial injury [30].
They represent a heterogeneous cell population originating
from a single multipotent progenitor cell (within the BM) and
consist of cells at different stages of maturation, including early
CD133
+
/VEGFR2
+
or more mature CD34
+
/VEGFR2
+
phenotypes
[31]. Impaired functioning of the EPC has been thought to be
involved in the pathogenesis and angiogenesis in SSc [32,33].
4. The immune system response in SSc
Microvascular endothelial cell injury and apoptosis is a central
event in the pathogenesis of SSc vasculopathy that leads to
immune system activation [34].
In human fibrotic skin diseases, apoptotic endothelial cells
could only be detected in early inflammatory disease stages of
SSc and localized SSc [35].
The alteration of both innate and adaptive immune response
plays a prominent role in early SSc pathophysiology and
includes the increased presence and altered functions of inflam-
matory cells and products in target tissues, such as the skin and
lungs, together with a prominent type I interferon (IFN) signa-
ture. Polymorphisms in IFN-regulatory factors confer an
increased risk of SSc, and IFN excess is evident in the blood
and skin of a large percentage of SSc patients [36].
Interestingly, among T cells (CD4
+
T cells), the type 2 T helper
(TH2) cells – characterized by secretion of IL-4 and IL-13 – are
more expressed in SSc than TH1 cells, which primarily secrete
anti-fibrotic IFNγ (Figure 3) [37]. In the CD4
+
Tcell population,
T regulatory (Treg) cells, which represent 5–15% of them, have
started being studied during the last decade in order to under-
stand their possible role in the development of SSc. In the
medical literature, the decreased functional capacity as well as
the low number of circulating Treg cells in SSc patients, usually
associated with a decrease in FOXP3 expression, have been
described [38,39].
Otherwise, SSc patients with an active disease may have
an increase in the number of these circulating cells. Of note,
recent findings demonstrated that Treg cells can contribute
to SSc development by their transformation to pathogenic
effector T cells [38].
In addition, the conversion of circulating Treg into Th17 cells
as well as skin-resident Treg to Th2 cells producing inflamma-
tory and profibrotic cytokines respectively, has been demon-
strated in SSc [38,40]. Other than regulatory T cells, angiogenic
T cells were observed to be increased in peripheral blood of SSc
patients, primarily in those patients with digital ulcers com-
pared to patients without digital ulcers and in patients showing
Figure 3. The early homing of the immune/inflammatory cells within the perivascular area (T cells, B cells, monocytes/macrophages) and platelets, further create in
systemic sclerosis a toxic milieu for the microcirculation, together with the high production of cytokines/chemokines and specific or functional autoantibodies. The
number of capillaries decreases and the fibrotic reaction starts.
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a late nailfold videocapillaroscopy (NVC) patter compared to
those with early/active NVC patterns [41].
Despite these results, the functional role in the pathogen-
esis of SSc and the possible involvement in fibrosis need to be
understood and clarified.
High levels of IL-6 in SSc correlate with the extent of skin
involvement and may anticipate poor long-term outcomes [42].
Chemokines also play important roles in angiogenesis and
fibrosis. Serum and tissue levels of C-C motif chemokine 2
(CCL2; also known as MCP1), CCL3 (also known as MIP1α), IL-
8 and CCL18 are increased in SSc patients and correlate with
disease severity and progression (Figure 3) [43].
Plasmacytoid dendritic cells infiltrate the skin of SSc
patients and are chronically activated, leading to secretion of
interferon-α (IFN-α) and of the small chemokine platelet factor
4 (PF4; also known as CXCL4) which are both hallmarks of the
disease [44].
On the other hands, an evident B cell activation produces
several autoantibodies (AAb) targeting a variety of nuclear,
cytoplasmatic, and extracellular autoantigens are the hallmark
of SSc and are observed at the time of first diagnosis in more
than 95% of patients (Figure 3) [45]. Some of these AAbs are
highly specific for SSc [46].
Many of the AAbs found in SSc do not directly contribute
to disease pathogenesis but are used as routine markers for
diagnosis and prognosis of organ involvement [47].
In diffuse cutaneous SSc (dcSSc) anti-topoisomerase AAbs
(ATA), formerly known as anti-Scl70 AAbs, are more preva-
lent, whereas anticentromere AAbs (ACA) are more frequent
in limited cutaneous SSc (lcSSc).
A possible pathogenic role of ATA in SSc has been suggested
following its binding to fibroblasts and induced adhesion and
activation of cocultured monocytes [48]. This observation might
provide an explanation for the amplification of the fibrogenic
cascade in ATA-positive SSc patients.
In patients with isolated Raynaud syndrome, the presence
of ACA has been reported to predict the likelihood that these
patients will progress to SSc [49].
In general, ACA positive patients have a better prognosis
and show lower mortality than SSc patients with other anti-
nuclear AAbs (ANA); however, 50% will eventually die from
pulmonary arterial hypertension (PAH) [45].
Similarly to ATA, also anti-RNA polymerase I/III AAbs (anti-
RNAP) are typically associated with a more rapidly progressive
dcSSc. Interestingly, the presence of anti-RNAP, especially the
presence of anti-RNAP III, is strongly associated with renal
crisis and malignancy [46,47,50].
Other AAbs that are highly specific for SSc include anti-Th/To
ribonucleoprotein (RNP) AAbs; anti-fibrillarin/U3RNP and anti-
U11/U12RNP AAbs, and anti- U1RNP AAbs [45].
5. The functional autoantibodies in SSc: new
insights
There is increasing evidence that generally functional AAbs
exhibit pathogenic features by binding to their target mole-
cule, where they induce abnormal activation or inhibition of
crucial cell functions directly related to disease pathogenesis.
Functional AAbs have been observed also in SSc patients
and are directed against G protein-coupled receptor (GPCR),
tyrosine kinase receptors, or other proteins like matrix metal-
loproteinases (Figure 3) [51].
AAbs binding the platelet-derived growth factor receptor
(PDGFR) have been the first functional AAbs described in SSc
and have been shown to contribute to the pathogenesis of
the diseases via activation of fibroblasts and fibroblast-like
cells [52].
However, heterogeneous set of anti-PDGFR AAbs involved
in SSc pathogenesis seems to show distinctive functional
properties with opposite effects.
AAbs against angiotensin II type 1 receptor (AT1R) and
endothelin type A receptor (ETAR) are GPCRs that are widely
expressed on cells of the vascular system and have been
detected in sera of SSc patients [53].
Anti-AT1R and anti-ETAR AAbs were found in nearly all SSc
patients and high levels are associated with severe SSc manifesta-
tions such as digital ulcers, PAH, and LF: predicting cardiovascular
complications and mortality, especially in SSc-related PAH [54].
Both AT1R and ETAR act agonistically as demonstrated by
the induction of ERK 1/2 phosphorylation and increased TGFβ
messenger RNA (mRNA) expression in ECs [53].
Finally, anti-endothelial cell Abs (AECA) are detected in 25–85%
of patients with SSc and were associated with severe vascular
involvement [29]. In a recent review, Mihai C and colleagues
described how the ubiquitous nuclear protein CENP-B is the
main target of AECA in patients with lcSSc and AECA frompatients
with dcSSc, with or without anti-topoisomerase I (anti-Scl-70)
antibodies, bind to endothelial cell topoisomerase I, suggesting
that classical autoantibodies such as CENP-B and topoisomerase
I could act as AECA [55].
An increased ability of AECA to adhere to ECs and to
induce EC activation, AAb-dependent cell-mediated cytotoxi-
city, and endothelial apoptosis has been demonstrated in
several in vitro studies [56].
These effects can be linked to SSc pathogenesis, especially to
EC altered function. The existence of functional AAbs among the
heterogeneous AECA group has been demonstrated, in particu-
lar AECA targeting ICAM-1 that have been shown to induce the
inflammatory activation at the level of ECs [57].
One important aspect is that the detection and identification
of functional AAbs together their molecular targets might repre-
sent a possible way of specific treatments, especially during the
early step of SSc, before the overt manifestations of disease
progression.
6. The macrophage M1/M2 polarization and the
fibrotic lung in SSc: new insights
In early SSc, circulating progenitor cells, such as monocytes
recruited from the bone marrow, migrate in the tissues together
with T cells and macrophage precursors, and create a perivascular
infiltrate with a changed phenotype (Figure 3) [58].
Macrophages, after differentiation from monocytes, can
generate different phenotypes of cells distinguished on the
basis of different surface markers as classically activated (M1)
and/or alternatively activated (M2) macrophages [58].
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Generally, M1 macrophages are effector phagocytes with
an increased microbicidal or tumoricidal capacity and produce
proinflammatory cytokines like TNF-alpha, IL-6, IL-1, whereas
M2-polarized macrophages produce anti-inflammatory cyto-
kines, mostly IL-4, IL-13 and IL-10 [59].
During the tissues wound healing or at the peak of the
profibrotic late immune response, M2 macrophages are con-
sidered as inducers of tissue fibrosis in SSc. Therefore, M2
macrophages partially suppress M1 responses (by their polar-
ization) and promote extracellular matrix (ECM) protein
synthesis, including profibrotic cytokine release as well as
potentiate the antiinflammatory response by inducing Th2
effector activities [59].
Interestingly, ET-1 seems to induce the M2 polarization in
cultured human macrophages, a process apparently con-
trasted by the action of the ET-1 receptor antagonism (ETA/B
RA), suggesting possible clinical implications in those fibrotic
diseases characterized by increased ET-1 concentrations, such
as SSc but also type 2 diabetes [60].
Therefore, in SSc the persistency of tissue damage is not
efficiently repaired, especially due to the immune system
activation. The increased and sustained release of cytokines,
and growth factors, especially from Th2 cells and M2 macro-
phages, induces in SSc a progressive fibrotic state that
involves tissues and organs [61].
Importantly, major gene signatures related to phenotype,
activation and migration of macrophages have been shown
to be significant for the progressive pulmonary fibrosis,
pointing to macrophages as key players in SSc lung involve-
ment [62,63].
Intriguingly, imbalance in macrophage phenotype and
macrophage activation, have been lately considered essential
for the development of inflammatory-autoimmune, fibrotic,
infective and neoplastic disorders all characterized by lung
involvement [64–69].
As mentioned, macrophages have been initially categorized
as M1 or M2, mirroring T cells categories. M1 macrophages
express specific phenotype markers, including toll-like recep-
tors (i.e. TLR2 and TLR4) and the co-stimulatory molecules
CD80 and CD86, and are involved in triggering intensive
inflammation and tissue damage [70].
On the contrary, M2 macrophages primarily express the
mannose receptor-1 (CD206) and macrophage scavenger recep-
tors (CD204 and CD163), and they are associated with T helper
(Th) 2 response, tissue repair as well as fibrosis [71,72].
However, classifications based on a wider spectrum of
phenotypes of which M1 and M2 subsets would constitute
the two extremes have been reported [73].
Moreover, it was observed that themajority of alveolarmacro-
phages combine M1 and M2 features in steady state and that the
mixed M1/M2 phenotype can be altered by HIV infection [74].
Interestingly, a recent preliminary study demonstrated
higher percentages of circulating mixed M1/M2 monocytes/
macrophages in SSc patients compared to healthy subjects
(Figure 3) [75]. In addition, a very recent study showed for the
first time, that higher circulating mixed M1/M2 monocyte/
macrophage cell percentages are associated with interstitial
ling disease (ILD), systolic pulmonary artery pressure (sPAP)
and anti-Scl-70 positivity in SSc patients, opening the path for
research on their possible role as pathogenic or biomarker
elements for SSc lung involvement [76].
7. Players for the fibrotic process in SSc: current
understanding
The fibrotic tissue is characterized by the large presence of α-
SMA positive cells, apoptosis-resistant myofibroblasts that
secrete not only ECM proteins but also TGF-β and other profi-
brotic mediators (Figure 4) [77].
Monocyte-derived circulating mesenchymal progenitor
cells (fibrocytes), as well as tissue-specific trans-differentiation
from pericytes and ECs all contribute to the expansion of the
myofibroblasts (Figure 4).
Fibrosis with progressive tissue accumulation of ECM pro-
teins like collagens, elastin, glycosaminoglycans, tenascin and
fibronectin in skin and multiple organs, is a prominent patho-
logical finding and distinguishing hallmark of clinically overt
SSc (limited cutaneous and diffuse cutaneous SSc).
Interestingly, increased concentrations of alternatively spliced
isoforms of ECM proteins such as fibronectin (fibronectin-EDA
(FnEDA)) and tenascin-C have been found to be accumulated
within fibrotic tissues like it happen in advanced hyperplastic
synovial tissue in rheumatoid arthritis (RA) [78–81].
In fact, in RA and SSc, it has been shown that at least tenascin-
C isoform can directly bind to TLR4 on stromal cells and induce
fibroblast activation and myofibroblast differentiation [82].
The progressive and increased deposition of ECM proteins,
especially at the beginning fibronectin and tenascin followed by
increased COL-1 and less fibrillin with their crosslinkings, increases
skin and organ stiffness and reduces their elasticity, resulting in
a real mechanical stress. The tissuemechanical stress that arises in
SSc progression, further maintain fibroblast activation and further
intensify the progression of the fibrotic process [83].
Fibroblasts, are differentiated in activated myofibroblasts as
principal effector cells during the progression of the disease, in
a profibrotic cellular milieu produced by the early immune/
inflammatory reaction and formed by growth factors of different
origin and selected cytokines (i.e. IL13, IL-6), developmental
pathways, ET-1 and other soluble mediators (Figure 1) [84].
Beyond chronic fibroblast activation, SSc fibrosis represents
a failure to terminate the normal tissue repair to the immune/
inflammatory stimulus.
Asmatter of fact, the early innate immune system contribution
via Toll-like receptors signaling, matrix-generated biomechanical
stress via integrins signaling, hypoxia and oxidative cellular stress
with associated cell apoptosis, is implicated from the beginning
and is crucial in perpetuating the SSc fibrotic process [85].
In addition, studies have identified intrinsic alterations in SSc
fibroblasts resulting from epigenetic changes, as well as altered
microRNA expression (in particular miR-29, miR-155) that might
underlie the persistent activation phenotype of the cells [86,87].
Interestingly, miR-155 was found significantly increased in
SSc (including dermal fibroblasts) and the highest expressing
miRNA in lung fibroblasts [88].
Its expression was dependent on inflammasome activation
as miR-155 expression could be blocked when inflammasome
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signaling was inhibited. In the absence of miR-155, inflamma-
some-mediated collagen synthesis could not be induced but
was restored when miR-155 was expressed in miR-155-deficient
fibroblasts (murine model) [88].
Among growth factors and cytokines implicated in SSc, TGF-
β (a pleiotropic cytokine) is considered the main modulator of
fibrosis and is produced from macrophages and other cells as
inactive precursor, is accumulated within the ECM and is con-
verted to its biologically active form via integrin-mediated acti-
vation [89].
In detail, TGF-β signaling involves sequential phosphor-
ylation of the type I TGF-β receptor (TGFR1), activation of
Small mother against decapentaplegic (SMAD, namely
SMAD2–SMAD3) dependent and independent intracellular
signaling pathways and their binding to a consensus SMAD-
binding element found in TGF-β -inducible profibrotic
genes [90,91].
In addition, further intracellular mediators of the TGF-β
signaling pathways, implicated in SSc pathogenesis, involve
the activation of the kinase cascade including MAPK1 and
MAPK3 (mitogen-activated protein kinases originally called as
ERK2 and ERK1, extracellular signal-regulated kinases) [92].
8. The fibrotic process: new insights
Basically, ET-1 is a potent vasoconstrictor that in humans is
encoded by the EDN1 gene and produced by vascular endothe-
lial cells.
In particular, it was found that ET-1 produced by activated ECs
contributes to myofibroblast activation using TGF-β machinery
via an ET-1/TGF-β receptor complex in SSc [93].
However, it is now evident that activated fibroblasts produce
ET-1, that is able to increase fibronectin synthesis in normal and
SSc human skin fibroblasts, suggesting further important roles
also for ET-1 in the pathogenesis of the SSc fibrotizing process
(Figure 4) [94–96].
Inhibitors of ET-1/2 receptors (bosentan, macitentan) have
been found to interfere with the profibrotic action of TGF-β,
blocking in detail the ET-1 receptor portion of the ET-1/TGF-β
receptor complex [97].
In fact, an important study has shown that ET-1 induces an
increased expression of fibronectin mRNA in cultured perito-
neal mesothelial cells and contributes to the ability of TGF-β to
promote a profibrotic phenotype in human fibroblasts [98].
In conclusion, both the early prolonged vasoconstrictor
activity (i.e. RP in 90–98% of SSc patients) exerted by ET-1
and the later profibrotic effect by ET-1 on fibroblasts, seem to
contribute to the pathogenesis of SSc.
The first sign occurring in of patients with SSc is RP, an abnor-
mal reactivity of digital microvasculature under cold and other
stimuli which highlights the central role of microvascular damage
before the fibrotic process in the pathogenesis of SSc [99,100].
Recently, epithelial-to-mesenchymal transition (EMT) and
EndoMT represented a newly recognized types of cellular
trans-differentiation, and these processes have emerged as
further possible sources of tissue myofibroblasts in presence
of damage [101].
Figure 4. The scleroderma fibrotic tissue is characterized by the large presence of α-smooth muscle actin-positive myofibroblasts that secrete not only extracellular
matrix proteins but also TGFβ and other profibrotic mediators, like endothelin-1 (ET-1). Monocyte-derived circulating mesenchymal progenitor cells (fibrocytes), as
well as tissue-specific transdifferentiation from pericytes, adipocytes, and endothelial cells, all contribute to the expansion of the myofibroblasts.
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Despite evidence suggesting that EndoMT is involved in
not only pathological but also physiological conditions such as
normal wound healing, the underlying molecular mechanisms
involved in this process are now better recognized in SSc
[102–104].
EndoMT can be induced by TGF-β and together with ET-1,
both seem to be pivotal players in the development of SSc
fibrosis [105].
As matter of fact, it is well documented that the activation
of TGF-β intracellular transcription factors is responsible for
the production of other profibrotic molecules, such as indeed
ET-1 [106].
Moreover, TGF-β-induced ET-1 release has been associated
with the fibrotic response of skin and lung SSc fibroblasts, and
in clinical management of SSc patients the inhibition of the
both ET-1 receptors with antagonist drugs bosentan and maci-
tentan, was recently found to downregulate the EndoMT in
cultures of normal and SSc fibroblasts [107,108].
In addition, TGF-β contributed to myofibroblast increase in
the damaged tissues also promoting the transition of peri-
cytes, a process that seems to involve the activation of several
molecules such as ADAM12, a protein highly expressed in skin,
mesenchymal stem cells and fibroblasts of SSc patients, and its
inhibition may contribute to attenuate the profibrotic activity
of all these cells [28].
Together with a fibroblast-myofibroblast transition (FMT)
involved in the profibrotic process, it has been recently
reported limited to animal models, that myofibroblasts are
produced from adiponectin-positive intradermal progenitor
cells and the process was confirmed by adipocyte phenotype
investigations and termed adipocyte-myofibroblast transition
(AMT) [109].
This pathway demonstrates very rapid dynamics and in
24 hours after stimulation with TGF-β1, dermal adipocytes
were in a transition state and expressed the myofibroblast α-
SMA marker. Interestingly in animal models cell fat mapping
showed that the majority of the myofibroblasts accumulated
in dermal fibrosis originate from dermal adipocytes [109].
The phenomenon was first showed long time ago, when
was demonstrated that an acute thermic or mechanical injury
to adipose tissue, induces a fast phenotypic transformation of
the mature adipocytes into fibroblast-like cells with a primitive
phenotype [110].
Interesting, high levels of miR-155 suppress adipogenic
differentiation and keep preadipocytes in an undifferentiated
state thus inhibiting adipogenesis [111,112].
In conclusion, adipocytes from interfacial local white adi-
pose tissue (WAT) adjacent to the fibrotic area in SSc are
phenotypically different from bulk adipocytes and seem
involved in pathogenesis of SSc [113].
9. Conclusions
The progression of the mechanisms implicated in the complex
pathophysiology of SSc are clinically mirrored by the patient
complications, and partially morphologically reflected by the
safe observation of the microvascular alterations that are clas-
sified/scored by nailfold videocapillaroscopy as progressive
‘early’, ‘active’ and ‘late’ patterns (Figure 5) [114–118].
The complex nature of SSc suggest and early and combined
treatment of the patient with different approaches [119].
10. Expert opinion
The pathogenesis of SSc include epigenetic/genetic, vascular
and immunologic mechanisms, that are all implicated in the
progressive fibrosis that mainly characterize the overt disease,
and all are major targets for the actual and/or incoming new
disease modifying therapeutic (DMARD) approaches.
Of note, the heterogeneity of clinical manifestations in SSc
patients and the current limited therapeutic approaches repre-
sent important aspects and, at the same time, limitations in
the study of SSc pathogenesis that further highlight the com-
plexity of the disease management.
As matter of fact, the majority of the actual and incoming
therapies for SSc, exert the final action to contrast the pro-
gression of fibrosis, even if the drugs have been originally
planned for a different activity, for example vasodilation or
immunosuppression.
The use of vasodilators in SSc is a reality from several years,
acting on different targets but showing sometimes unex-
pected actions, as recently shown for instance by the use of
the prostacyclin receptor agonist selexipag, synthesized for
the treatment of pulmonary arterial hypertension (PAH) in SSc.
Selexipag and mainly its active metabolite (ACT-333,679),
have been found for the first time to potentially interfere with
Figure 5. The progression of the mechanisms implicated in the complex pathophysiology of SSc are clinically mirrored by the observation of the microvascular
alterations that are classified/scored by the safe nailfold videocapillaroscopy as progressive ‘early’, ‘active’ and ‘late’ patterns.
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the profibrotic activity of cultured SSc fibroblasts/myofibro-
blasts at least in vitro, through the downregulation of fibro-
genic Erk1/2 and Akt kinase intracellular signaling [120]. This
effect is recognized as complementary/secondary to the origi-
nal supposed vasodilatory main action.
The ET-1 receptor (ETA and ETB) antagonists (sitaxsentan,
macitentan, and bosentan) represent another kind of therapy
programmed originally to treat PAH in SSc, and that was also
found to exert antifibrotic actions by reducing the synthesis of
COL-1, fibronectin and fibrillin-1 in primary cultures of skin
fibroblasts from SSc patients [97,121].
In addition, and even more relevant, both ETR antagonists
(bosentan and macitentan) were found to inhibit the EndoMT,
a complex biological process in which in SSc, endothelial cells
lose their specific markers and acquire a mesenchymal or
myofibroblastic phenotype, that mean fibrosis [108].
A further example, of unexpected antifibrotic activity, arises
from the use of CTLA-4Ig in SSc in order to achieve an immuno-
suppressive action by interacting/blocking the costimulatory
molecules (CD80/CD86) expressed on activated immune
cells [122].
As matter of fact, a couple of studies showed unexpected
antifibrotic actions on experimental dermal fibrosis and on
cultured circulating fibrocytes and fibroblasts from SSc
patients after treatment with CTLA-4Ig [123,124].
Keeping the immunosuppressive treatment as fundamental
in autoimmune diseases like SSc, the use of rituximab (B-cell
depleting drug), has been shown again to exert antifibrotic
actions by reducing the skin myofibroblasts infiltration in
treated SSc patients [125].
In addition, a 2-treatment course (months 0/6) with ritux-
imab, appeared to be well tolerated and seemed to have
potential efficacy for skin disease and stabilization of internal
organ status in early diffuse cutaneous SSc [126].
A further remodeling effect on microvasculature was sig-
naled following the treatment of SSc patients with rituximab
for years, in fact a reduction of capillary loss was observed, as
evaluated by nailfold capillaroscopy [127].
Similar reduction of microvascular damage, as evaluated by
nailfold videocapillaroscopy, was previously described in SSc
patients treated with cyclosporine A or cyclophosphamide, in
order to obtain immunosuppression [128,129].
In conclusion, new target treatments are under evaluation for
the management of fibrosis in SSc patients, in particular lung
fibrosis, i.e., Nintedanib, a tyrosine kinase inhibitor that interact
with several profibrotic pathways implicated in the pathogenesis
at least of pulmonary SSc fibrosis and/or M2 macrophages.
Advances in translational research, including possible
limitations, have undoubtedly open new horizons for the
advanced and targeted therapy in SSc.
In the next years the systematic early combination therapy
of SSc patients with vasodilators, immunosuppressive and
antifibrotic drugs (with direct and indirect activity), should
successfully downregulate the disease progression from the
beginning and in particular the whole fibrotic process.
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